Symbiotec Pharmalab Limited IPO Details
Factual IPO information from public filings. Not investment advice.
Issue Details
- Price Band
- ₹938 – ₹988
- Lot Size
- 15 shares
- Min. Investment
- ₹14,820
- Total Issue Size
- ₹1,757 Cr
- 1,77,86,442 shares
- Fresh Issue
- ₹150.27 Cr
- 15,21,261 shares
- Offer for Sale
- ₹1,606.72 Cr
- 1,62,65,181 shares
- Face Value
- ₹2 per share
- Issue Type
- Book-built IPO
- Listing At
- BSE, NSE
- Shares Pre-Issue
- 6,27,34,851
- Shares Post-Issue
- 6,42,56,112
Lot Size & Investment
1 lot = 15 shares
Retail (min)
1 lot · 15 shares
Retail (max)
13 lots · 195 shares
S-HNI (min)
14 lots · 210 shares
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail | 1 | 15 | ₹14,820 |
| Small HNI (S-HNI) | 14 | 210 | ₹2,07,480 |
| Big HNI (B-HNI) | 68 | 1,020 | ₹10,07,760 |
Financial Performance
Restated figures in ₹ crore, unless stated otherwise
| Period | Mar-26 | Mar-25 | Mar-24 |
|---|---|---|---|
| Assets | 1,780.79 | 1,579.65 | 1,294.79 |
| Total Income | 872.26 | 755.98 | 723.33 |
| Profit After Tax | 109.9 | 96.79 | 100.06 |
| EBITDA | 231.97 | 206.11 | 177.04 |
| Net Worth | 1,158.64 | 821.15 | 720.68 |
| Reserves & Surplus | 1,145.95 | 810.03 | 709.54 |
| Total Borrowing | 387.91 | 540.92 | 247.21 |
Key Performance Indicators
| Period | Mar-26 | Mar-25 |
|---|---|---|
| RoNW (%) | 9.48 | 11.79 |
| EPS (₹) | — | 17.82 |
| P/E (pre-issue) | — | 55.44 |
| P/E (post-issue) | — | 56.81 |
About Symbiotec Pharmalab Limited
Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The company serves domestic and international markets across regulated and emerging regions. With over 30 years of industry experience, Symbiotec Pharmalab has evolved from a lab-scale steroidal hormone API manufacturer in 1995 into an industrial-scale, backward-integrated manufacturing platform. The company has approvals from the United States Food and Drug Administration (US FDA), European Union Good Manufacturing Practices (EU-GMP), Ministry of Food and Drug Safety, Korea, and other global regulatory organisations. As of June 30, 2025, the company operated two industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes (MT) and fermentation capacity of 300 kilolitres. Symbiotec Pharmalab focuses on research-driven manufacturing, quality compliance, and sustainable production processes. It supports the pharmaceutical, nutraceutical, and wellness industries by providing high-quality ingredients aligned with global standards. Competitive Strengths: Global leadership in corticosteroid and steroidal hormone APIs. Long-standing relationships with domestic and international customers. Fully invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and a strong regulatory track record. Continuous investment in research and development, supported by strong technological capabilities among Indian industry peers. Ability to leverage its scientific expertise and existing capabilities to expand its total addressable market and develop intellectual property-driven offerings.
Company Information
- Book running lead managers
- JM Financial Ltd.
- Avendus Capital Pvt.Ltd.
- Motilal Oswal Investment Advisors Ltd.
- Nomura Financial Advisory & Securities (India) Pvt.Ltd.
- Registered office
- 385/2,, Pigdamber, Rau,, Mhow,, Indore, Madhya Pradesh, 453331